Literature DB >> 27330057

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.

Adam Sharp1, Jonathan Welti1, Julian Blagg2, Johann S de Bono3.   

Abstract

Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ©2016 AACRSee related article by Yang et al., p. 4466. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27330057      PMCID： PMC5302169          DOI： 10.1158/1078-0432.CCR-16-1137

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

2.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

3.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

4.  Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding.

Authors:  Derek N Lavery; Iain J McEwan
Journal:  Biochemistry       Date:  2008-02-20       Impact factor: 3.162

5.  Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Authors:  Yu Chi Yang; Carmen Adriana Banuelos; Nasrin R Mawji; Jun Wang; Minoru Kato; Simon Haile; Iain J McEwan; Stephen Plymate; Marianne D Sadar
Journal:  Clin Cancer Res       Date:  2016-05-02       Impact factor: 12.531

6.  EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Authors:  Lucas J Brand; Margaret E Olson; Preethi Ravindranathan; Hong Guo; Aaron M Kempema; Timothy E Andrews; Xiaoli Chen; Ganesh V Raj; Daniel A Harki; Scott M Dehm
Journal:  Oncotarget       Date:  2015-02-28

7.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Authors:  Jae-Kyung Myung; Carmen A Banuelos; Javier Garcia Fernandez; Nasrin R Mawji; Jun Wang; Amy H Tien; Yu Chi Yang; Iran Tavakoli; Simon Haile; Kate Watt; Iain J McEwan; Stephen Plymate; Raymond J Andersen; Marianne D Sadar
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

Review 8.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

9.  Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Authors:  Jonathan Welti; Daniel Nava Rodrigues; Adam Sharp; Shihua Sun; David Lorente; Ruth Riisnaes; Ines Figueiredo; Zafeiris Zafeiriou; Pasquale Rescigno; Johann S de Bono; Stephen R Plymate
Journal:  Eur Urol       Date:  2016-04-23       Impact factor: 20.096

10.  BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Authors:  Irfan A Asangani; Kari Wilder-Romans; Vijaya L Dommeti; Pranathi M Krishnamurthy; Ingrid J Apel; June Escara-Wilke; Stephen R Plymate; Nora M Navone; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Mol Cancer Res       Date:  2016-01-20       Impact factor: 5.852
View more
  10 in total

1.  Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation.

Authors:  Andrea Clocchiatti; Soumitra Ghosh; Maria-Giuseppina Procopio; Luigi Mazzeo; Pino Bordignon; Paola Ostano; Sandro Goruppi; Giulia Bottoni; Atul Katarkar; Mitchell Levesque; Peter Kölblinger; Reinhard Dummer; Victor Neel; Berna C Özdemir; G Paolo Dotto
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Authors:  Margaret M Centenera; Luke A Selth; Esmaeil Ebrahimie; Lisa M Butler; Wayne D Tilley
Journal:  Cold Spring Harb Perspect Med       Date:  2018-12-03       Impact factor: 6.915

3.  Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Authors:  Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava
Journal:  Mol Cancer Res       Date:  2017-06-12       Impact factor: 5.852

4.  Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.

Authors:  Yezi Zhu; Adam Sharp; Courtney M Anderson; John L Silberstein; Maritza Taylor; Changxue Lu; Pei Zhao; Angelo M De Marzo; Emmanuel S Antonarakis; Mindy Wang; Xingyong Wu; Yuling Luo; Nan Su; Daniel Nava Rodrigues; Ines Figueiredo; Jonathan Welti; Emily Park; Xiao-Jun Ma; Ilsa Coleman; Colm Morrissey; Stephen R Plymate; Peter S Nelson; Johann S de Bono; Jun Luo
Journal:  Eur Urol       Date:  2017-09-01       Impact factor: 20.096

5.  Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.

Authors:  Ashley T Fancher; Yun Hua; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2019-09-06       Impact factor: 1.738

6.  HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.

Authors:  Zhongbo Du; Luo Li; Wei Sun; Xiao Wang; Yao Zhang; Zhixiong Chen; Mengjuan Yuan; Zhen Quan; Nanjing Liu; Yanni Hao; Ting Li; Jinhua Wang; Chunli Luo; Xiaohou Wu
Journal:  Int J Oncol       Date:  2018-04-12       Impact factor: 5.650

7.  Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway.

Authors:  Wei Sun; Luo Li; Zhongbo Du; Zhen Quan; Mengjuan Yuan; Honglin Cheng; Yingying Gao; Chunli Luo; Xiaohou Wu
Journal:  Oncol Rep       Date:  2019-03-07       Impact factor: 4.136

Review 8.  Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.

Authors:  Namrata Khurana; Suresh C Sikka
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

9.  Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.

Authors:  Yezi Zhu; Susan L Dalrymple; Ilsa Coleman; S Lilly Zheng; Jianfeng Xu; Jody E Hooper; Emmanuel S Antonarakis; Angelo M De Marzo; Alan K Meeker; Peter S Nelson; William B Isaacs; Samuel R Denmeade; Jun Luo; W Nathaniel Brennen; John T Isaacs
Journal:  Oncogene       Date:  2020-09-28       Impact factor: 9.867

Review 10.  Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer.

Authors:  Sanjay Kumar; Sanjeev Gurshaney; Yori Adagunodo; Erica Gage; Shezreen Qadri; Mahak Sharma; Shalie Malik; Upender Manne; Udai P Singh; Rajesh Singh; Manoj K Mishra
Journal:  Front Biosci (Landmark Ed)       Date:  2018-06-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.